A microfluidic platform for single cell fluorometric granzyme B profiling

20Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.

Abstract

Granzyme B (GrB) is an essential cytotoxic effector in cancer immunotherapy as it can be a potential biomarker to predict the efficacy of immunotherapies including checkpoint inhibitors. Monitoring the Granzyme B activity in cells would help determine a patient’s clinical response to treatment and lead to better treatment strategies by preventing administration of ineffective therapies and avoid adverse events resulting in a delay in subsequent treatment. Methods: A microfluidic device with hydrodynamic traps and pneumatic valving system was fabricated using photo and soft lithography. Single cell Granzyme B (GrB) activity was detected and measured fluorometrically using a commercial assay kit with a peptide substrate containing GrB recognition sequence (Ac-IEPD-AFC) and AFC (7-Amino-4-trifluoromethylcoumarin) label. Fluorescence was observed and measured using a confocal microscope with CSU-W1 scanner unit and CCD camera as well as an inverted microscope with photodetector. Model cells (NK-92, GrB-transduced Jurkat, and THP1 cells) and human PBMCs from healthy donor and lung cancer patients including an anti-PD-1 antibody treated patient were profiled of its GrB activity as proof of concept. Results: GrB expression from the model cells was found to be markedly different. NK-92 cells were found to have higher GrB activity than the GrB-transduced Jurkat cells. THP-1 was found to have relatively no significant activity. A marked increase in GrB expression was also observed in anti-PD-1 treated lung cancer patient sample in comparison to PBMC from a healthy donor. TCR+ Ig-G4+ PBMC cells were found to have high activity which signifies a clear response to PD-1 blockade. Conclusion: As proof of concept, we have shown the capability of a microfluidic platform to measure GrB production through a single cell enzymatic activity assay. Our platform might be a promising tool for evaluating the sensitivity of immunotherapies and identifying specific T cell subset responsible for the anti-tumor response.

References Powered by Scopus

PD-1 blockade induces responses by inhibiting adaptive immune resistance

5400Citations
N/AReaders
Get full text

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: A comprehensive review of registration trials and future considerations

1000Citations
N/AReaders
Get full text

Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells

423Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Immunotherapy discovery on tumor organoid-on-a-chip platforms that recapitulate the tumor microenvironment

51Citations
N/AReaders
Get full text

Tumor-on-a-chip platforms to study cancer-immune system crosstalk in the era of immunotherapy

46Citations
N/AReaders
Get full text

Immunocompetent cancer-on-chip models to assess immuno-oncology therapy

45Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Briones, J. C., Espulgar, W. V., Koyama, S., Yoshikawa, H., Park, J. H., Naito, Y., … Saito, M. (2020). A microfluidic platform for single cell fluorometric granzyme B profiling. Theranostics, 10(1), 123–132. https://doi.org/10.7150/thno.37728

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 9

64%

Researcher 3

21%

Professor / Associate Prof. 1

7%

Lecturer / Post doc 1

7%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 6

33%

Engineering 5

28%

Medicine and Dentistry 4

22%

Agricultural and Biological Sciences 3

17%

Save time finding and organizing research with Mendeley

Sign up for free